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ALTHOUGH the initiating events of Crohn’s disease are
unknown, models of experimental colitis have pro-
vided new insights in the immunologically mediated
pathways of mucosal inflammation. In Crohn’s dis-
ease activated mucosal T lymphocytes produce pro-
inflammatory cytokines within the mucosal compart-
ment. With this understanding, there has been a shift
in past years from the use of unspecific anti-inflam-
matory agents  (corticosteroids,  aminosalicylates)  to
the use of  immunomodulatory drugs (azathioprine,
methotrexate). Moreover, novel strategies have been
designed  for  specific  targets  in  Crohn’s  disease,  in
particular T lymphocytes and cytokines. In an open
label  study  treatment  of  steroid-refractory  Crohn’s
disease with anti- CD4+ antibodies was well tolerated
and  showed  clinical  benefit.  However,  a  sustained
depletion of the CD4+ cells precluded further clinical
trials.  In  controlled  clinical  studies,  anti-tumour
necrosis factor (TNF-a ) antibodies induced complete
remissions and few side effects were observed. One
study suggested efficacy in active Crohn’s disease of
recombinant  interleukin-10.  Long  term  treatment
studies  will  have  to  answer  questions  about  the
indications for use, benefit and toxicity. Altogether,
these results hold promise for future management of
Crohn’s  disease,  where  disease-modifying  interven-
tions and strategies that effectively maintain disease
remission will play a key role.
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Introduction
Crohn’s  disease  is  a  chronic  inflammation  of  the
gastrointestinal  tract,  characterised by relapses  and
periods of disease remission. As the aetiology of this
disease is unknown, medical treatment is symptomat-
ical  and  aimed  at  surppressing  the  inflammatory
response. To date, corticosteroids remain the main-
stay treatment of active Crohn’s disease, resulting in a
rapid initial reduction of symptoms in approximately
70% of patients.1 Unfortunately, many patients either
become steroid-dependent, steroid resistant or suffer
from side effects. An alternative therapeutic option is
provided by immunomodulatory drugs such as azo-
thioprine, methotrexate and cyclosporine.2 The use
of  these  agents  is  limited  by  their  low  efficacy,
inadequate selectivity and substantial short and long
term toxicity.
Recently,  specific  mediators  of  the  immune
response  have  been  identified.  In  Crohn’s  disease
there  seems  to  be  an  enhanced  mucosal  T  cell
activation.  Here,  we  briefly  review  several  new
immunomodulatory agents designed for specific tar-
gets,  in  particular  T  lymphocytes  and  cytokines,
which have been studied in experimental and clinical
inflammatory bowel disease.
Lessons from Colitis Models
Various  experimental  animal  models  of  inflamma-
tory  bowel  disease  have  partially  unravelled  the
complex  mucosal  network  of  cytokine  interac-
tions.4,5 The  main  conclusions  from  these  studies
can be summarised as follows: firstly, different sub-
populations  of  T-cells  within  the  CD4  positive
(CD4+)  compartment  have  a  pivotal  role  in  either
initiation  or  control  of  the  immune  mediated
mucosal  inflammation. This  paradigm  is  supported
by observations  made in T -cell mediated models of
inflammatory bowel disease. IL-2 deficient (IL-2null)
mice crossed with b 2mnull mice, that lack functional
CD8+ cells develop a spontaneous colitis.6 Transfer
of  CD45RBhigh CD4+  T-cells  (considered  to  be  a
Th1  precursor  population)  from  normal  mice  to
SCID  mice  (that  lack T -  and  B-cells)  resulted  in  a
severe  colitis,  suggesting  a  causative  role  for  this
CD4+  subset.7 The most  efficient  mean  to  prevent
this  intestinal  inflammation  was  to  co-transfer
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phocyte population).8,9 Hence, lack of specific anti-
inflammatory T -cells  may  lead  to  uncontrolled  acti-
vation within the CD4+ compartment. Secondly, the
importance  of  anti-inflammatory  mechanisms  is
exemplified by a  mouse  model  that  has  a targeted
disruption  in  the  IL-10  gene  (IL-10  KO  mouse).
These mice develop a severe colitis with increased
local levels of pro-inflammatory cytokines.10 Thirdly,
in  the  IL-10  KO  mouse  and  in  the  CD45RBhigh
transfer  model  colitis  does  not  occur  in germ  free
animals.  Therefore,  the  normal  intestinal  flora  (or
their  antigens)  are  necessary  for  activation  of  the
uncontrolled immune response in the  mouse  mod-
els mentioned. Finally, increased production of pro-
inflammatory  cytokines,  including  tumour  necrosis
factor-a (TNF-a )  and  interferon  g (IFNg ),  is  an
important  finding  in  experimental  models  where
colitis is caused by chemical irritation of the intesti-
nal mucosa by hapten induced T cell activation (e.g.
TNBS model) or by T cell transfer.11,12
Collectively, these data seem to indicate that  the
normal mucosal immune response is strictly regulated
and  actively  suppressed. An  ill-controlled,  antigen-
dependent (CD4+) T lymphocyte activation will result
in a high production of pro-inflammatory cytokines
within the mucosal compartment and in inflamma-
tory bowel disease.
Interestingly, the (repeated) administration of TNF-
a , IL-12 and IFNg neutralising antibodies and recom-
binant  IL-10  resulted  in  amelioration  of  mucosal
inflammation in several models of T cell dependent
inflammation.13,14,15
Analogous  to  the  findings  in  mouse  models,  in
patients with Crohn’s disease the mucosal production
of  various  pro-inflammatory  cytokines  is  increased,
most likely as a consequence of chronic CD4+ T -cell
activation.16 The aim of new clinical interventions in
Crohn’s disease is either to decrease the activity of
CD4+ cells, to neutralise pro-inflammatory cytokines
such  as  TNF-a ,  or  to  increase  anti-inflammatory
cytokines that inhibit Th1 differentiation such as IL-
10.17,18,19
Interference with T-cell Function
Two different ways of influencing T -cell function in
inflammatory bowel disease have been investigated.
First,  a  rather  unspecific  immunosuppressive
approach  using  anti-CD4+  monoclonal  antibodies
was investigated in patients with Crohn’s disease in
order to assess safety and potential efficacy. The CD4
molecule  is  necessary  for T-cell  signal  transduction
following  presentation  of  antigen  by  MHC  class  II
molecules.  In  an  uncontrolled  pilot  study,  12
patients with steroid refractory Crohn’s disease were
treated with a mouse-human chimeric antibody (cM-
T412). This antibody depletes the number of circu-
lating  CD4+ cells, and interferes with CD4-depend-
ent  activation  of  T -cells.  After  seven  consecutive
infusions of 10, 30 or 100mg daily only minor side
effects,  such  as  a  febrile  reaction  after  the  first
infusion, were experienced. Treatment resulted in a
significant  dose  dependent  reduction  of  the  CDAI
(10  weeks  24%  and  52%   in  the  two  highest  dose
groups) and circulating CD4+ count. Other lympho-
cyte  subpopulations  showed  no  major  changes.20
This therapy demonstrated to be well tolerated and
no  opportunistic  infections  occurred.  No  further
controlled  trials  have  been  performed,  because  of
the  resulting  CD4  depletion  that  in  some  patients
sustained for more than 12 months following treat-
ment.  Ongoing  research  also  revealed  that  only
subsets  of  activated T  cells  within  the  CD4+  com-
partment  are  important  in  the  pathogenesis  of
inflammation in Crohn’s disease.7 A reduction of all
CD4+ T cells would no longer seem to be a primary
goal of immunotherapy.
Secondly, antibodies that neutralise a 4b 7 integrin
have been proposed as another way to interfere with
the T -cell activation in Crohn’s disease. The a 4b 7 ‘gut
homing integrin’, a molecule important for selectively
directing lymphocytes to the mucosal compartment,
mediates adherence of lymphocytes to the activated
cells of high endothelial venules (HEV’s) or Payer’s
patches that express MadCAM-1. It is responsible for
the  specific  recirculation  of  T  cells  through  the
intestinal mucosa.21,22,23 Indeed, in cottontop tamar-
ins, a 4b 7 neutralising antibodies reduced the severity
of a spontaneously occurring colitis.24
Cytokine-targeting Therapies
In recent years TNF-a has been identified as a major
pro-inflammatory  cytokine  in  Crohn’s  disease.18,25
TNF-a is  a  17kD  non-glycosylated  cytokine  mainly
produced by monocytes, macrophages and activated
T -cells. After release, which is a result of clipping of
the  signal  peptide  by  a  specific  metalloproteinase,
TNF-a is released as a bioactive 51kD trimer. Unclip-
ped TNF-a remains  membrane  bound  and  is  also
biologically  active  upon  contact  with  cells,  that
express a receptor for TNF-a (TNFR-1 or TNFR-2).26 Of
relevance for IBD are the abilities of TNF-a to recruit
circulating inflammatory cells to local tissue sites of
inflammation, to induce oedema, to activate coagula-
tion  activation,  an  its  pivotal  role  in  granuloma
formation. Both in mice models and in humans, colitis
is characterised by mucosal expression of high levels
of TNF-a and  IFNg mRNA. The  severity  of TNBS-
induced  colitis  could  be  reduced  by  (repeated)
administration of neutralising anti-TNF-a or anti-IFNg
antibodies. Conversely, in TNF-a deficient mice colitis
could not be induced by TNBS administration.15 The
chimeric  monoclonal  antibody  infliximab,  also
known as cA2, has been studied in more patients with
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This  genetically  constructed  IgG1  murine-human
chimeric  monoclonal  antibody  binds  to  both  the
soluble subunit  and membrane bound precursor  of
human TNF-a .28
In  the  first  controlled  clinical  trial,  108  patients
with moderate to severe Crohn’s disease resistant to
standard therapy, received placebo or cA2 at a dose of
either 5, 10, 20mg/kg.29The primary endpoint was a
clinical response as defined by a decrease of the CDAI
by more than 70 points, 4 weeks following administra-
tion of the antibody. The placebo response rate was
17%, versus 81%  of the patients given 5mg/kg of cA2,
50% in the 10mg/kg group, and 64% in the 20mg/kg
group.  Administration  of  the  antibody  as  a  single
infusion resulted in remissions that were maintained
in almost  all  patients  that  had  responded to  initial
treatment during the 3-month study period. Although
no important  short-term  side  effects  were  encoun-
tered, the long-term effects of chronic or intermittent
use remain unknown.
Preliminary results of a controlled study to evaluate
the  efficacy  and  safety  of  cA2  for  the  closure  of
enterocutaneous fistulae in Crohn’s disease showed
an impressive reduction in the number of draining
fistulae (publication in preparation).
In another study, 31 patients with active Crohn’s
disease received a single infusion of a different anti-
TNF-a antibody (the humanised antibody CDP571).
Disease activity was reduced in the CDP571-treated
patients: the CDAI dropped after two weeks from 263
to  167,  in  the  placebo  group  no  difference  was
observed.30 In an open label trial 15 ulcerative colitis
patients showed consistent improvement in disease
activity in the initial 2 weeks after a single infusion of
CDP571 and the treatment was well tolerated.29
The mechanism of action of anti-TNF-a antibodies
remains  to  be  revealed.  Neutralisation  of  released
TNF-a or  membrane-bound  TNF-a may  be
involved.25,28
In  conclusion,  anti-TNF-a treatment  may  induce
clinical responses in patients with (steroid refractory)
Crohn’s disease and possibly also in ulcerative colitis.
The  induction  of  remission  occurs  rapidly,  and  is
associated with a significant  reduction  of intestinal
inflammation. Large phase III controlled clinical trials
soon will start to study if maintenance of remission
can be obtained with repeated infusions.
Alternative ways of interfering with production or
release TNF-a are under investigation. These include
TNF-a binding  proteins,  which  have  been  con-
structed  by  placing  the TNF-a binding  domains  of
either  TNFR-1  or  TNFR-2  on  an  immunoglobulin
backbone.  In  a  large  controlled  trial  with  185
rheumatoid arthritis patients, one of these proteins
(recombinant human tumour necrosis factor receptor
(p75)-Fc  fusion  protein)  proved  to  be  safe,  well
tolerated, and associated  with  improvement  in the
inflammatory  symptoms.32 Another  approach  is  to
increase the intracellular cyclic AMP concentrations
thereby decreasing the TNF-a transcription. However
using oxpentifylline, this approach showed no clin-
ical  efficacy  in  Crohn’s  disease.33 Several  metal-
loproteinase inhibitors can reduce TNF-a production
in  vitro  and  in  vivo,  and  some  are  in  clinical
development. By the inhibition of clipping TNF-a , the
release of TNF-a is blocked and the membrane bound
TNF-a remains unaffected or may even accumulate.
Clinical  trials  will  have  to  answer  the  question
whether released or membrane bound TNF-a is more
important in the process of inflammation.34
Another candidate to restore the delicate balance
between  proinflammatory  and  anti-inflammatory
cytokines in the intestinal mucosa is recombinant IL-
10  (rIL-10). This  is  a  18kD  cytokine,  produced  by
macrophages, monocytes and certain T and B cells. IL-
10 is a potent inhibitor of activated macrophages and
T cells by down regulation of IL-1, IL-6, IL-8 and TNF-
a .35 In addition, IL-10 interferes with antigen depend-
ent  T  cell  proliferation  by  reducing  HLA  class  II
expression.36 Consequently,  IL-10  favours Th2-type
responses  and  B  cell  activation.37 A  phase  II  dose
escalating study in 46 steroid-refractory patients with
active Crohn’s disease indicated the safety of a one
week daily intravenous infusion of 0.5–25g/kg rIL-10.
The  therapy  was  well  tolerated  and  although  the
study was not designed to assess efficacy, 50%  of the
rIL-10  treated  patients  versus  23%  of  the  placebo
patients  had  a  complete  clinical  remission.38 How-
ever, preliminary data of a controlled trial investigat-
ing the efficacy of subcutaneous administration of rIL-
10  in Crohn’s  disease  patients  showed less benefit
(publication in preparation).
Conclusions
Experimental and clinical studies indicate that inhibi-
tion of specific inflammatory pathways may reduce
severity  of  inflammatory  bowel  disease.  Controlled
clinical  trials  showed  the  potential  benefit  of  anti-
TNFa antibodies  in  Crohn’s  disease  patients  who
were steroid-refractory or had enterocutaneous fistu-
lae.  Recombinant  IL-10  seems  less  efficacious  in
decreasing  activity  of  Crohn’s  disease  when  com-
pared to anti-TNF-a . However, since IL-10 may inhibit
a Th1–response it might prevent flare-ups or maintain
remissions in Crohn’s disease. Future studies will have
to  answer  questions  about  the  indications  for  use,
benefit and toxicity of long term use and timepoint of
administration. Disadvantages of cytokine-based ther-
apies  are  possible  induction  of  allergic  reactions,
antibody formation to the ‘foreign’ peptides that may
lessen therapeutic effects, and increased susceptibil-
ity  to  opportunistic  infections  or  malignancy  (e.g.
lymphoma’s). Finally, these therapies are expected to
be quite expensive.
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nisms  underlying  inflammatory  bowel  disease  will
result  in  more  therapeutical  strategies  in  Crohn’s
disease. These  will  include  targeting  cytokine  gene
transcription  factors  and  cytokine-based  gene  ther-
apy.39 For example, the transient local expression of
adenovirus-IL-4 in TNBS colitis in rats was shown to
have  a  beneficial  effect.40 The  main  challenge  for
future  management  of  Crohn’s  disease  will  be  to
develop  disease-modifying  interventions  as  well  as
strategies that effectively maintain disease remission.
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